Hong Kong, September 27, 2026
Akeso, Inc. announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase 3 clinical trial evaluating cadonilimab in combination with chemotherapy against chemotherapy with or without nivolumab as first-line treatment for patients with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The trial is designed to evaluate the efficacy and safety of cadonilimab across geographically and ethnically diverse patient populations and to investigate whether dual PD-1/CTLA-4 immune checkpoint blockade can improve outcomes beyond current first-line treatment approaches.
Akeso Advances Global Phase 3 Development
COMPASSION-37 represents an important step in Akeso’s international clinical development strategy for cadonilimab. The randomized, global, head-to-head Phase 3 study is being conducted across multiple regions and will compare the cadonilimab-based regimen with established treatment approaches. The study is co-led by international investigators including Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center, Professor Markus Möhler of Johannes Gutenberg University Mainz, Professor Jiafu Ji of Peking University Cancer Hospital & Institute, and Professor Lin Shen of Peking University Cancer Hospital. Their involvement brings experience from previous research that helped establish nivolumab plus chemotherapy as an important first-line strategy for advanced gastric and gastroesophageal cancers. The study addresses an important clinical question in advanced gastric cancer, where treatment response can vary according to tumor biology and PD-L1 expression. PD-1 inhibitor-based combinations with chemotherapy are established treatment approaches for HER2-negative advanced gastric cancer, but the magnitude of benefit can differ among patient subgroups. COMPASSION-37 is therefore designed to investigate whether a dual immune-checkpoint approach can provide clinically meaningful benefit across different PD-L1 expression levels and patient populations.
Cadonilimab Targets PD-1 and CTLA-4
Cadonilimab is Akeso’s first-in-class PD-1/CTLA-4 bispecific antibody, designed to simultaneously target two important immune-checkpoint pathways. By combining PD-1 and CTLA-4 blockade within a single antibody molecule, the treatment is intended to enhance anti-tumor immune responses through complementary mechanisms. The approach is being investigated in multiple cancer types, including gastric, liver, lung, cervical and pancreatic cancers. According to Akeso, cadonilimab has been evaluated in more than 40 clinical studies covering more than 20 indications, with multiple Phase 3 and registrational programs ongoing. The COMPASSION-37 program builds on earlier clinical evidence from COMPASSION-15, a randomized, double-blind, placebo-controlled Phase 3 study involving 610 patients with HER2-negative advanced gastric or G/GEJ adenocarcinoma. Akeso reported that cadonilimab plus chemotherapy significantly reduced the risk of death compared with the control group in the overall study population, including patients with different levels of PD-L1 expression. The company said these findings provided the scientific basis for further international evaluation in the global COMPASSION-37 trial.
Global Trials Expand Gastric Cancer Program
Akeso is also evaluating cadonilimab in earlier-stage gastric cancer. A U.S.-based Phase 2 study, NCT07631000, is currently enrolling patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma. The study is evaluating cadonilimab combined with FLOT chemotherapy as a perioperative treatment approach. Akeso said the study is intended to generate evidence that could support a future international Phase 3 program in the perioperative setting. The company said the development program now spans different stages of gastric cancer, from advanced unresectable or metastatic disease to potentially curable, localized disease. This broader strategy allows cadonilimab to be evaluated across multiple treatment settings while generating clinical evidence in different patient populations. The global COMPASSION-37 trial will be particularly important in determining whether the cadonilimab-based combination can demonstrate improved outcomes compared with current treatment approaches.
Cadonilimab has already received regulatory approvals in China, including approval in 2022 for relapsed or metastatic cervical cancer and subsequent approval for first-line gastric or gastroesophageal junction cancer in 2024. It was also approved in 2025 for first-line persistent, recurrent or metastatic cervical cancer in combination with chemotherapy-based regimens. The latest global Phase 3 program represents another step in Akeso’s efforts to expand international development of its immuno-oncology portfolio. The initiation of COMPASSION-37 provides a significant clinical development milestone for Akeso and cadonilimab. The study’s results will ultimately determine whether dual PD-1/CTLA-4 blockade can provide additional benefit over established first-line treatment strategies in advanced gastric cancer, particularly across different PD-L1 expression groups. The ongoing international program will provide further evidence on the candidate’s efficacy, safety and potential role in global gastric cancer treatment.
Source: Akeso press release



